Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- ZI +20.5%, ASPN +15.8%, BRKR +8%, METC +6.9% (guidance), LDOS +4%, WM +3.3%, TAP +2.9%, ROIV +2.6%, AN +2%, INCY +1.8%, SB +1.7%, HWM +1.7%, PFG +1.5%, SAFE +0.9%, BB +0.7% (guidance), TRU +0.7%
Other news:
- KALV +29.2% (results from the phase 3 KONFIDENT clinical trial)
- LIAN +16.3% (completion of strategic review)
- JBLU +15.2% (Carl Icahn discloses 9.91% stake)
- STTK +14.8% (announces a worldwide drug discovery collaboration with Ono Pharmaceutical Co)
- TRIP +11.2% (forming a special committee evaluating proposals)
- EXAI +8.5% (decided to terminate the employment of Andrew Hopkins as the Company's Chief Executive Officer and Principal Executive Officer)
- BMR +8.3% (prices offering of 1714200 ordinary shares at $7.00 per share)
- GPI +3.2% (acquiring RRR Automotive Group; increases dividend)
- KRYS +3% (receives FDA fast track designation for inhaled oncology candidate KB707 to treat solid tumors of the lung)
- AEP +2.5% (entered last night into an agreement with Icahn Capital L.P. and certain of its affiliates under which Hunter C. Gary senior managing director at Icahn Enterprises L.P. and Henry P. Linginfelter retired executive vice president of Southern Company Gas will join AEP's Board of Directors)
- HCC +2.3% (special cash dividend)
Analyst comments:
- GSK +1.3% (upgraded to Buy from Neutral at Citigroup)